 |
市場調查報告書
商品編碼
1402571
柳氮磺吡啶市場：依產品類型、依應用、依最終用戶、按地區Sulfasalazine Market, By Product Type, By Application, By End User, By Geography |
||||||
柳氮磺吡啶的全球市場規模預計將從2023年的20.1億美元成長到2030年的29.6億美元，預測期內複合年成長率為5.7%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年 | 2022年 | 2023年市場規模 | 20.1億美元 |
| 實績資料 | 2018-2021 | 預測期 | 2023-2030 |
| 預測期複合年成長率 | 5.70% | 2030年市場規模預測 | 29.6億美元 |
柳氮磺吡啶是一種藥物，屬於緩解疾病抗風濕藥物 (DMARD)，主要用於治療發炎性腸道疾病，如類風濕性關節炎、潰瘍性大腸炎和克隆氏症。該藥物以其磺胺吡啶和 5-胺基水楊酸 (5-ASA) 的獨特組合而聞名，這兩者都有助於提高其治療功效。在類風濕性關節炎中，柳氮磺胺吡啶可抑制免疫系統反應，減少發炎，並減輕關節疼痛和腫脹。它通常被作為綜合治療計劃的一部分來控制這種慢性自體自體免疫疾病的症狀和進展。發炎性腸道疾病疾病涉及胃腸道的慢性發炎，柳氮磺吡啶的發炎特性可能有益於治療與潰瘍性大腸炎和克隆氏症相關的症狀。柳氮磺吡啶的 5-ASA 成分被認為在胃腸道內的發炎作用中發揮重要作用。柳氮磺吡啶通常是口服給藥，其效果通常需要一段時間才能顯現。與任何藥物一樣，由於可能存在副作用，其使用受到醫療保健專業人員的密切監控。柳氮磺吡啶廣泛用於治療某些發炎疾病，由於其不同的作用機制，在這些疾病的醫療管理中仍然是一種有價值的治療選擇。
市場動態
柳氮磺吡啶市場的成長受到幾個關鍵因素的影響。首先，全球自體自體免疫疾病和胃腸道疾病盛行率的上升是一個關鍵促進因素。隨著人們對這些疾病的認知和診斷的增加，對柳氮磺吡啶和類似藥物的需求可能會增加。其次，人口高齡化，尤其是新興市場的人口老化，正在促進市場擴張。老年人更容易患發炎疾病，增加了對柳氮磺吡啶等長期管理和治療方案的需求。第三，製藥業加大研發力道可能推出更先進、更有效的柳氮磺吡啶製劑，進一步推動市場成長。
然而，市場也可能面臨挑戰，例如替代治療方法的可用性以及與柳氮磺吡啶相關的潛在副作用。醫療保健系統的監管變化和定價壓力可能會影響市場動態。
本研究的主要特點
- 該報告對全球柳氮磺吡啶市場進行了詳細分析，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率（CAGR%）。
- 它還揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
- 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
- 它根據公司亮點、產品系列、主要亮點、財務實績和策略等參數，介紹了全球柳氮磺吡啶市場的主要企業。
- 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的資訊。
- 柳氮磺吡啶全球市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
- 相關人員可以透過用於分析全球柳氮磺吡啶市場的各種策略矩陣來促進決策。
第1章 研究目的與前提
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章市場動態、法規及趨勢分析
- 市場動態
- 提高認知和診斷
- 與先進治療方法的競爭
- 聯合治療
- 影響分析
- 主要亮點
- 監管場景
- 產品發布/核准
- PEST分析
- 波特的分析
- 併購場景
第4章全球柳氮磺吡啶市場－冠狀病毒(COVID-19) 大流行的影響
- 新型冠狀病毒感染疾病（COVID-19）的流行病學
- 供需面分析
- 經濟影響
第5章全球柳氮磺吡啶市場，依產品類型，2018-2030
- 2023年及2030年市場佔有率分析（%）
- 與前一年同期比較成長分析，2019-2030
- 細分市場趨勢
- 非專利磺吡啶
- 2018-2030年市場規模及預測、與前一年同期比較成長率
- 柳氮磺吡啶品牌
- 2018-2030年市場規模及預測、與前一年同期比較成長率
第6章全球柳氮磺吡啶市場，依應用分類，2018-2030
- 2023年及2030年市場佔有率分析（%）
- 與前一年同期比較成長分析，2019-2030
- 細分市場趨勢
- 類風濕性關節炎
- 2018-2030年市場規模及預測、與前一年同期比較成長率
- 克隆氏症
- 2018-2030年市場規模及預測、與前一年同期比較成長率
- 潰瘍性大腸炎
- 2018-2030年市場規模及預測、與前一年同期比較成長率
- 其他發炎性腸道疾病
- 2018-2030年市場規模及預測、與前一年同期比較成長率
第 7 章全球柳氮磺吡啶市場，依最終用戶分類，2018-2030 年
- 2023年及2030年市場佔有率分析（%）
- 與前一年同期比較成長分析，2019-2030
- 細分市場趨勢
- 醫院
- 2018-2030年市場規模及預測、與前一年同期比較成長率
- 診所
- 2018-2030年市場規模及預測、與前一年同期比較成長率
- 門診手術中心
- 2018-2030年市場規模及預測、與前一年同期比較成長率
- 其他（學術研究機構等）
- 2018-2030年市場規模及預測、與前一年同期比較成長率
第8章全球柳氮磺吡啶市場，按地區，2018-2030
- 2023 年和 2030 年按國家/地區分類的市場佔有率分析 (%)
- 2019-2030與前一年同期比較成長分析（按國家）
- 各國的趨勢
- 北美洲
- 2018-2030 年市場規模與按產品類型預測、與前一年同期比較成長率
- 2018-2030 年市場規模及應用預測、與前一年同期比較成長率
- 2018-2030 年市場規模與最終用戶預測、與前一年同期比較成長率
- 2018-2030 年市場規模及各國預測、與前一年同期比較成長率
- 美國
- 加拿大
- 拉丁美洲
- 2018-2030 年市場規模與按產品類型預測、與前一年同期比較成長率
- 2018-2030 年市場規模及應用預測、與前一年同期比較成長率
- 2018-2030 年市場規模與最終用戶預測、與前一年同期比較成長率
- 2018-2030 年市場規模及各國預測、與前一年同期比較成長率
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 歐洲
- 2018-2030 年市場規模與按產品類型預測、與前一年同期比較成長率
- 2018-2030 年市場規模及應用預測、與前一年同期比較成長率
- 2018-2030 年市場規模與最終用戶預測、與前一年同期比較成長率
- 2018-2030 年市場規模及各國預測、與前一年同期比較成長率
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 2018-2030 年市場規模與按產品類型預測、與前一年同期比較成長率
- 2018-2030 年市場規模及應用預測、與前一年同期比較成長率
- 2018-2030 年市場規模與最終用戶預測、與前一年同期比較成長率
- 2018-2030 年市場規模及各國預測、與前一年同期比較成長率
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
- 中東
- 2018-2030 年市場規模與按產品類型預測、與前一年同期比較成長率
- 2018-2030 年市場規模與應用預測、與前一年同期比較成長率
- 2018-2030 年市場規模與最終用戶預測、與前一年同期比較成長率
- 2018-2030 年市場規模及各國預測、與前一年同期比較成長率
- GCC
- 以色列
- 其他中東地區
- 非洲
- 2018-2030 年市場規模與按產品類型預測、與前一年同期比較成長率
- 2018-2030 年市場規模及應用預測、與前一年同期比較成長率
- 2018-2030 年市場規模與最終用戶預測、與前一年同期比較成長率
- 2018-2030年按國家/次區域分類的市場規模與預測、與前一年同期比較成長率
- 北非
- 中部非洲
- 南非
第9章競爭形勢
- Pfizer Inc.
- Teva Pharmaceuticals USA, Inc.
- Ipca Laboratories Ltd
- Novalab Healthcare
- Dr. Reddy's Laboratories, Inc.
- Actus Healthcare
- Medisoft Pharma
- OVERSEAS HEALTH CARE
- Astonea Labs Private Limited
- Fibovil Pharmaceuticals Pvt Ltd
第10章
- 調查方法
- 關於出版商
The global sulfasalazine market size is expected to grow from US$ 2.01 Bn in 2023 to US$ 2.96 Bn by 2030, at a CAGR of 5.7% during the forecast period.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 2.01 Bn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 5.70% | 2030 Value Projection: | US$ 2.96 Bn |
Sulfasalazine is a medication that falls under the category of disease-modifying antirheumatic drugs (DMARDs) and is primarily used in the treatment of inflammatory conditions, particularly rheumatoid arthritis and inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. The drug is known for its unique combination of sulfapyridine and 5-aminosalicylic acid (5-ASA), both of which contribute to its therapeutic effects. In the context of rheumatoid arthritis, sulfasalazine works by suppressing the immune system's response, mitigating inflammation, and helping to alleviate joint pain and swelling. It is often prescribed as part of a comprehensive treatment plan to manage the symptoms and progression of this chronic autoimmune disorder. Inflammatory bowel diseases involve chronic inflammation of the digestive tract, and sulfasalazine's anti-inflammatory properties are beneficial in treating symptoms associated with ulcerative colitis and Crohn's disease. The 5-ASA component of sulfasalazine is believed to play a key role in this anti-inflammatory action within the gastrointestinal tract. Sulfasalazine is typically administered orally, and its effectiveness often requires some time to become evident. Like any medication, it may have potential side effects, and its use is closely monitored by healthcare professionals. While widely used for specific inflammatory conditions, sulfasalazine's diverse mechanisms of action continue to make it a valuable therapeutic option in the medical management of these diseases.
Market Dynamics
The growth of the sulfasalazine market is influenced by several key factors. First, the rising incidence of autoimmune and gastrointestinal disorders globally is a significant driver. As awareness and diagnosis of these conditions increase, the demand for sulfasalazine and similar medications is likely to grow. Second, the aging population, particularly in developed countries, contributes to the expansion of the market. Older individuals are more susceptible to inflammatory diseases, increasing the need for long-term management and treatment options like sulfasalazine. Third, ongoing research and development in the pharmaceutical industry may lead to the introduction of more advanced and effective formulations of sulfasalazine, further propelling market growth.
However, the market may also face challenges, such as the availability of alternative treatment options and the potential for side effects associated with sulfasalazine. Regulatory changes and pricing pressures in healthcare systems can impact market dynamics.
Key features of the study:
- This report provides in-depth analysis of the global sulfasalazine market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global sulfasalazine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc., Teva Pharmaceuticals USA, Inc., Ipca Laboratories Ltd, Novalab Healthcare, Dr. Reddy's Laboratories, Inc., Actus Healthcare, Medisoft Pharma, OVERSEAS HEALTH CARE, Astonea Labs Private Limited. and Fibovil Pharmaceuticals Pvt Ltd
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global sulfasalazine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sulfasalazine market
Detailed Segmentation:
- Sulfasalazine Market Segmentation, By Product Type:
- Generic Sulfasalazine
- Branded Sulfasalazine
- Sulfasalazine Market Segmentation, By Application:
- Rheumatoid Arthritis
- Crohn's Disease
- Ulcerative Colitis
- Other Inflammatory Bowel Diseases
- Sulfasalazine Market Segmentation, By End User:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Others (Academic and Research Institutes etc.)
- Sulfasalazine Market Segmentation, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Top companies in Sulfasalazine Market
- Pfizer Inc.
- Teva Pharmaceuticals USA, Inc.
- Ipca Laboratories Ltd
- Novalab Healthcare
- Reddy's Laboratories, Inc.
- Actus Healthcare
- Medisoft Pharma
- OVERSEAS HEALTH CARE
- Astonea Labs Private Limited
- Fibovil Pharmaceuticals Pvt Ltd
Table Of Content
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Global Sulfasalazine Market, By Product Type
- Market Global Sulfasalazine Market, By Application
- Market Global Sulfasalazine Market, By End user
- Market Global Sulfasalazine Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rising awareness and diagnoses
- Competition from advanced therapies
- Combination therapies
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Sulfasalazine Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Sulfasalazine Market , By Product Type, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Generic Sulfasalazine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Branded Sulfasalazine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
6. Global Sulfasalazine Market , By Application, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Crohn's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Other Inflammatory Bowel Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
7. Global Sulfasalazine Market , By End User, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Others (Academic and Research Institutes etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
8. Global Sulfasalazine Market , By Region, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Country 2019-2030
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceuticals USA, Inc.
- Ipca Laboratories Ltd
- Novalab Healthcare
- Dr. Reddy's Laboratories, Inc.
- Actus Healthcare
- Medisoft Pharma
- OVERSEAS HEALTH CARE
- Astonea Labs Private Limited
- Fibovil Pharmaceuticals Pvt Ltd
- Analyst Views
10. Section
- Research Methodology
- About us
